Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

NCT03289962 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03289962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03289962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2017
Completion date
July 1, 2025
Enrollment
273 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer, head and neck cancer, melanoma, non-small cell lung cancer, other solid cancers, renal cancer, triple negative breast cancer